logo

Protagonist Therapeutics, Inc (PTGX)



Trade PTGX now with
  Date
  Headline
6/18/2018 7:08:12 AM Protagonist Announces Phase 1 And Pre-clinical Data On Hepcidin Mimetic PTG-300 Presented At EHA Annual Meeting
6/1/2018 7:05:09 AM Protagonist Therapeutics Reports Granting Of Inducement Award To Samuel Saks, Chief Development Officer
5/24/2018 4:33:13 PM Protagonist Therapeutics Names Samuel Saks As Chief Development Officer
3/26/2018 6:46:07 AM Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial Of PTG-100 For Ulcerative Colitis
3/7/2018 4:04:49 PM Protagonist Therapeutics Q4 Loss/share $0.15 Vs. Loss $0.67 Year Ago
1/4/2018 8:13:22 AM Protagonist Therapeutics Receives Two New US Patents For Peptide Drug Candidates PTG-100 And PTG-300
12/14/2017 6:34:38 AM Protagonist Therapeutics Announces Final Phase 1 Study Results With Novel Hepcidin Mimetic, PTG-300
12/14/2017 6:32:56 AM Protagonist Therapeutics Appoints Sarah Noonberg To Board Of Directors
10/11/2017 11:01:23 PM Protagonist Therapeutics Prices Public Offering Of 3.53 Mln Shares At $17.00/shr
10/11/2017 4:05:34 PM Protagonist Therapeutics Announces Proposed Public Offering Of Common Stock
9/20/2017 8:02:58 AM Protagonist Therapeutics Announces Preliminary Phase 1 Study Results With Novel Hepcidin Mimetic, PTG-300